// App-Quantinova.ai

PB1570 : A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE VERSUS IDELALISIB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (LOTIS-6)

Researchers

Presenter

  • Carmelo Carlo-Stella

Principal Investigators

  • Julien Depaus

  • Brian T. Hess

  • Edwin Kingsley

  • Pier Luigi Zinzani

  • David Ungar

  • Vivian Dai

  • Luqiang Wang

  • Kirit M. Ardeshna

Medical Centers

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Clinical Development,ADC Therapeutics America, Inc,Murray Hill, NJ,United States

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Department of Oncology and Hematology,Humanitas Clinical and Research Center - IRCCS and Humanitas University,Rozzano, Milano,Italy

  • Department of Medicine,Division of Hematology and Medical Oncology, Medical University of South Carolina,Charleston, SC,United States

  • Department of Hematology, CHU UCL Namur, Yvoir, Belgium

Locations

  • United Kingdom

  • United States

  • Italy

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

  • Solid malignancies

Biomarkers

  • Apparent diffusion coefficient

Drug/Treatment

  • Idelalisib

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multiple Arm

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT04699461

Sponsors

  • ADC Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved